Horizon Therapeutics PLC
NASDAQ:HZNP
Horizon Therapeutics PLC
Cash from Operating Activities
Horizon Therapeutics PLC
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Horizon Therapeutics PLC
NASDAQ:HZNP
|
Cash from Operating Activities
$1B
|
CAGR 3-Years
49%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
Alkermes Plc
NASDAQ:ALKS
|
Cash from Operating Activities
$401.4m
|
CAGR 3-Years
69%
|
CAGR 5-Years
32%
|
CAGR 10-Years
11%
|
|
Amarin Corporation PLC
NASDAQ:AMRN
|
Cash from Operating Activities
$6.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Prothena Corporation PLC
NASDAQ:PRTA
|
Cash from Operating Activities
-$133.9m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-15%
|
|
M
|
Mural Oncology PLC
NASDAQ:MURA
|
Cash from Operating Activities
-$194.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Horizon Therapeutics PLC's Cash from Operating Activities?
Cash from Operating Activities
1B
USD
Based on the financial report for Jun 30, 2023, Horizon Therapeutics PLC's Cash from Operating Activities amounts to 1B USD.
What is Horizon Therapeutics PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
37%
Over the last year, the Cash from Operating Activities growth was -26%. The average annual Cash from Operating Activities growth rates for Horizon Therapeutics PLC have been 49% over the past three years , 37% over the past five years .